Kannan Sridharan
Overview
Explore the profile of Kannan Sridharan including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
150
Citations
672
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Possible attenuation of gout risk by SGLT-2 inhibitors in patients using thiazide and loop diuretics
Sridharan K
Expert Rev Endocrinol Metab
. 2025 Mar;
:1-2.
PMID: 40088194
No abstract available.
2.
Sridharan K, Sivaramakrishnan G
BMC Cardiovasc Disord
. 2025 Mar;
25(1):180.
PMID: 40087557
Background: Triple antithrombotic therapy (TAT), combining dual antiplatelet therapy (DAPT) with oral anticoagulants, is commonly used in patients requiring long-term anticoagulation following acute coronary syndrome or percutaneous coronary intervention. However,...
3.
Sridharan K, Sivaramakrishnan G
BDJ Open
. 2025 Mar;
11(1):24.
PMID: 40069171
Background: Drug-associated gingival disorders can negatively impact on oral health. This study aimed to utilize the United States Food and Drug Administration Adverse Event Reporting System (USFDA AERS) to comprehensively...
4.
Sridharan K, Sivaramakrishnan G
J Clin Med
. 2025 Feb;
14(4).
PMID: 40004629
Amlodipine has recently been incidentally reported with angioedema and is frequently prescribed with renin-angiotensin-aldosterone system inhibitors (RAAS-i) for hypertension management. While RAAS-i drugs are known to cause angioedema, the risk...
5.
Sridharan K, Sivaramakrishnan G
Expert Opin Drug Saf
. 2025 Feb;
:1-10.
PMID: 39924461
Background: Setmelanotide is approved for genetically determined obesity. While clinical trials and clinical evidence and practice provide some insights, a comprehensive assessment of its adverse event profile is needed that...
6.
Sridharan K, Sivaramakrishnan G
J Clin Lipidol
. 2025 Feb;
PMID: 39924422
Background: Ezetimibe, a Niemann-Pick C1-like 1 inhibitor, is widely prescribed as a monotherapy or in combination with statins to reduce cholesterol levels. Although generally well-tolerated, concerns have emerged regarding the...
7.
Sridharan K, Sivaramakrishnan G
J Oral Maxillofac Surg
. 2025 Feb;
PMID: 39922223
Background: Osteonecrosis of the jaw (ONJ) is an adverse effect associated with medications such as monoclonal antibodies and small-molecule inhibitors. Purpose: This study assesses the association between monoclonal antibodies and...
8.
Sridharan K
Expert Opin Drug Saf
. 2025 Feb;
:1-16.
PMID: 39918872
Background: Alcohol Use Disorder (AUD) significantly affects global health, leading to physical deterioration and impacting personal and social relationships. This study aims to evaluate the adverse event profiles (AEP) of...
9.
Sridharan K, Alkhidir M
Expert Rev Endocrinol Metab
. 2025 Jan;
20(2):139-146.
PMID: 39835962
Background: Sodium-glucose cotransporter-2 inhibitors (SGLT2is) are known for their cardiovascular benefits, but their impact on serum uric acid levels is not well understood. This study evaluates the hypouricemic effects of...
10.